Oncternal Therapeutics, Inc. (ONCT) has 20 open-market insider trades by 11 insiders since 2020. The most active filer is Robert James Wills, Director.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Shanghai Pharmaceutical (USA) Inc. | 10% Owner | — | 1 | $5.0M | 2020-07-21 |
| Michael G. Carter | Dir | — | 1 | $300K | 2020-09-01 |
| Hazel M. Aker | — | — | 1 | $200K | 2020-07-21 |
| Robert James Wills | Dir | — | 3 | $154K | 2024-04-08 |
| James B. Breitmeyer | CEO | — | 2 | $86K | 2024-01-03 |
| Chase C. Leavitt | Secretary | — | 3 | $39K | 2024-01-03 |
| Richard G. Vincent | CFO | — | 3 | $38K | 2024-01-03 |
| David F. Hale | Dir | — | 2 | $26K | 2024-02-23 |
| Salim Yazji | Chief Medical Officer | — | 2 | $24K | 2024-01-03 |
| Daniel L. Kisner | Dir | — | 1 | $24K | 2020-07-21 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Robert James Wills | Director | Buy | $28K | 2024-04-08 |
| Robert James Wills | Director | Buy | $117K | 2024-03-28 |
| David F. Hale | Director | Buy | $9K | 2024-02-23 |
| Gunnar F. Kaufmann | Chief Scientific Officer | Buy | $10K | 2023-06-12 |
| Richard G. Vincent | CFO | Buy | $9K | 2023-04-13 |
| James B. Breitmeyer | CEO | Buy | $44K | 2023-04-13 |
Companies that share insiders with ONCT, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Chase C. Leavitt | Secretary | Buy | $7K | 2023-04-12 |
| Salim Yazji | Chief Medical Officer | Buy | $7K | 2023-04-12 |
| Richard G. Vincent | CFO | Buy | $7K | 2022-03-24 |
| Chase C. Leavitt | Secretary | Buy | $23K | 2022-01-27 |
| Salim Yazji | Chief Medical Officer | Buy | $17K | 2022-01-27 |
| James B. Breitmeyer | CEO | Buy | $42K | 2022-01-27 |
| Richard G. Vincent | CFO | Buy | $22K | 2022-01-27 |
| David F. Hale | Director | Sell | $17K | 2021-06-30 |
| Chase C. Leavitt | Secretary | Buy | $8K | 2021-06-11 |